Guillain-Barré syndrome market outlook with key growth drivers

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Guillain-Barre Syndrome Market Over The 2026–2030 Period?

The guillain-barre syndrome market size has shown strong expansion in recent years. It is forecast to grow from $0.64 billion in 2025 to $0.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.6%. Historically, this market’s development has been driven by factors such as enhanced recognition of autoimmune neurological conditions, the expansion of hospital-based neurology departments, broader availability of immunotherapy treatments, an increase in post-infectious complication cases, and improvements in critical care infrastructure.

The guillain-barre syndrome market is forecasted to achieve robust growth in the upcoming years. It is projected to expand to $0.83 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.4%. This anticipated growth is largely due to factors such as increased investments in neurology research, a rising demand for advanced immunomodulatory therapies, the expansion of specialized rehabilitation services, the growing adoption of digital neurological assessment tools, and a heightened focus on early intervention strategies. Prominent trends throughout the forecast period include the increasing application of intravenous immunoglobulin therapies, a rise in the use of plasma exchange procedures, an intensified emphasis on early neurological diagnosis, the continued expansion of specialized neurology care centers, and enhanced monitoring for autoimmune neurological disorders.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Which Factors Are Influencing The Growth Of The Guillain-Barre Syndrome Market?

The projected expansion of the guillain-barre syndrome market is anticipated to be fueled by the escalating prevalence of immunological diseases. These conditions manifest when the immune system functions improperly, either overreacting, underreacting, or being misdirected, leading to disorders such as autoimmune diseases, allergies, or immunodeficiencies. The rise in immunological diseases is attributed to factors like environmental shifts, lifestyle choices, improved diagnostic methods, and genetic predispositions. Immunological diseases can induce guillain-barré syndrome by initiating an autoimmune attack where the body’s immune system mistakenly targets peripheral nerves, causing inflammation and subsequent nerve damage. For example, a report from the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, published in July 2024, stated that by the end of 2022, approximately 39.5 million people globally were living with HIV, with 1.3 million new infections and 630,000 AIDS-related deaths documented that year. This figure increased to around 39.9 million people living with HIV worldwide in 2023. Consequently, the heightened risk of immunological diseases is propelling the guillain-barre syndrome market.

What Are The Different Segment Types In The Guillain-Barre Syndrome Market Segment Breakdown?

The guillain-barre syndrome market covered in this report is segmented –

1) By Type: Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN)

2) By Therapeutics: Intravenous Immunoglobulin (IVIG), Plasma Exchange, Other Therapeutics

3) By End User: Hospitals, Specialty Neurology Clinics, Rehabilitation Centers, Home Healthcare Settings

Subsegments:

1) By Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Classical AIDP, AIDP with Autonomic Involvement

2) By Miller Fisher Syndrome (MFS): Classical MFS, MFS With Ataxia, MFS With Ophthalmoplegia

3) By Acute Motor Axonal Neuropathy (AMAN): Classical AMAN, AMAN with Respiratory Involvement

Which Trends Are Influencing Demand In The Guillain-Barre Syndrome Market?

Leading companies in the guillain-barre syndrome market are prioritizing innovative drug development, such as monoclonal antibodies, to enhance treatment efficacy, address unmet clinical needs, and expand their market presence. Monoclonal antibodies are laboratory-engineered proteins designed to target specific antigens, helping modulate immune responses and improve therapeutic outcomes. For instance, in October 2023, Annexon Inc., a US-based biopharmaceutical company, received orphan drug designation by the European Medicines Agency (EMA) for its drug ANX005 for the treatment of guillain-barre syndrome (GBS). This is a monoclonal antibody targeting C1q, demonstrating early muscle strength improvements and reduced need for ventilation compared to IVIg, marking it as a significant therapeutic advancement.

Who Are The Well-Known Companies In The Guillain-Barre Syndrome Market?

Major companies operating in the guillain-barre syndrome market are Pfizer Inc., Roche AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Baxter International Inc., Biogen Inc., Horizon Therapeutics, Octapharma AG, Kedrion S.p.A., CSL Behring, Hansa Biopharma AB, Annexon Inc., Immunovant Inc., UCB S.A., Alexion Pharmaceuticals, Argenx SE, Grifols S.A., LFB S.A

Get The Full Guillain-Barre Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Where Is The Guillain-Barre Syndrome Market Most Concentrated Geographically?

North America was the largest region in the guillain-barre syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Guillain-Barre Syndrome Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-global-market-report

Browse Through More Reports Similar to the Global Guillain-Barre Syndrome Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Narcolepsy Market Report 2026

https://www.thebusinessresearchcompany.com/report/narcolepsy-global-market-report

Progressive Ataxia And Weakness Disorders Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795